VRCA

Verrica Pharmaceuticals Inc. [VRCA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

VRCA Stock Summary

Top 10 Correlated ETFs

VRCA


Top 10 Correlated Stocks

VRCA


In the News

12:22 29 Mar 2024 VRCA

Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript

Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript

07:30 29 Mar 2024 VRCA

Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024

WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, February 29, 2024 to provide a corporate update and discuss the Company's financial results for the fourth quarter and full-year ended December 31, 2023.

07:44 29 Mar 2024 VRCA

7 Potential Short-Squeeze Stocks Poised for Rapid Gains

You want potential short-squeeze stocks that could have the bears running for cover? Great, we got ‘em right here!

10:10 29 Mar 2024 VRCA

Here's What Insiders Are Buying to Wrap Up the Year

As the year wound to a close, biotechs were in focus among the notable insider purchases.

09:03 29 Mar 2024 VRCA

Buffett, Dollar Tree Purchases Highlight Pre-Christmas Insider Buying

Ahead of the holiday weekend (and the end of the year), Berkshire Hathaway made another big buy of the Oracle of Omaha's favorite oil and gas exploration and production company.

01:49 29 Mar 2024 VRCA

Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today?

Shares of Verrica Pharmaceuticals (NASDAQ: VRCA ) skyrocketed on Friday thanks to positive late-stage clinical trial results. Specifically, Verrica — along with its development and commercialization partner Torii Pharmaceutical — reported positive top-line results from its Phase 3 trial of TO-208 for the treatment of molluscum contagiosum in Japan.

07:00 29 Mar 2024 VRCA

Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023

WEST CHESTER, Pa., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, November 9, 2023, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2023.

08:00 29 Mar 2024 VRCA

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

WEST CHESTER, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that that Ted White, Verrica President and CEO, will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 5:00 pm ET. The Company will also be participating in one-on-one meetings during the conference.

03:16 29 Mar 2024 VRCA

Why Shares of Verrica Pharmaceuticals Are Plummeting on Monday

Verrica focuses on dermatology therapeutics. The company just received approval for its first marketed product.

07:00 29 Mar 2024 VRCA

Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET

WEST CHESTER, Pa., July 24, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Company has entered into a non-binding term sheet for a term loan facility of up to $125 million, which the Company expects to close by the end of this week.

VRCA Financial details

Company Rating
Neutral
Market Cap
212.52M
Income
-66.5M
Revenue
5.12M
Book val./share
0.43
Cash/share
1.5
Dividend
-
Dividend %
-
Employees
100
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-5.93
Forward P/E
-7.48
PEG
-0.75
P/S
80.35
P/B
6.67
P/C
3.94
P/FCF
-8.81
Quick Ratio
7.77
Current Ratio
8.06
Debt / Equity
2.2
LT Debt / Equity
2.17
-
-
EPS (TTM)
-1.45
EPS next Y
-0.79
EPS next Q
-0.45
EPS this Y
82.72%
EPS next Y
-45.52%
EPS next 5Y
-232.07%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-31.85%
EPS Q/Q
-1.85%
-
-
-
-
SMA20
-3.37%
SMA50
-14.43%
SMA100
40.22%
Inst Own
30.02%
Inst Trans
0.89%
ROA
-49%
ROE
-94%
ROC
-0.57%
Gross Margin
87%
Oper. Margin
-1524%
Profit Margin
-1484%
Payout
-
Shs Outstand
42.42M
Shs Float
25.31M
-
-
-
-
Target Price
10
52W Range
2.86-7.755
52W High
-15.57%
52W Low
+195.5%
RSI
65.15
Rel Volume
0.34
Avg Volume
172.3K
Volume
58.21K
Perf Week
24.68%
Perf Month
11.93%
Perf Quarter
50%
Perf Half Y
50%
-
-
-
-
Beta
1.869
-
-
Volatility
0.34%, 0.3%
Prev Close
4.6%
Price
5.91
Change
9.65%

VRCA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
000.440.270.11
Net income per share
-1.12-1.82-1.44-0.81-1.48
Operating cash flow per share
-1.1-1.21-1.02-0.55-0.85
Free cash flow per share
-1.13-1.27-1.05-0.56-0.86
Cash per share
2.492.622.611.011.53
Book value per share
2.611.321.211.180.44
Tangible book value per share
2.611.321.211.180.44
Share holders equity per share
2.611.321.211.180.44
Interest debt per share
0.012.951.770.111.05
Market cap
395.63M287.7M247.18M93.53M331.91M
Enterprise value
386.57M312.33M274.84M60.78M307.87M
P/E ratio
-14.15-6.32-6.35-3.38-4.95
Price to sales ratio
0020.610.3664.77
POCF ratio
-14.43-9.52-8.96-5.01-8.6
PFCF ratio
-14.08-9.08-8.68-4.93-8.52
P/B Ratio
6.098.727.582.3416.79
PTB ratio
6.098.727.582.3416.79
EV to sales
0022.96.7360.08
Enterprise value over EBITDA
-12.85-7.87-8.93-2.91-4.93
EV to operating cash flow
-14.1-10.34-9.96-3.26-7.98
EV to free cash flow
-13.76-9.86-9.66-3.21-7.91
Earnings yield
-0.07-0.16-0.16-0.3-0.2
Free cash flow yield
-0.07-0.11-0.12-0.2-0.12
Debt to equity
02.151.330.042.2
Debt to assets
00.960.540.030.53
Net debt to EBITDA
0.3-0.62-0.91.570.39
Current ratio
19.391.661.6111.314.55
Interest coverage
0-13.25-7.2-9.8-15.96
Income quality
0.970.710.790.760.58
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
002.251.930
Research and developement to revenue
001.331.353.96
Intangibles to total assets
00000
Capex to operating cash flow
0.020.050.030.020.01
Capex to revenue
00-0.07-0.03-0.07
Capex to depreciation
-2.65-6.42-1.87-0.42-0.43
Stock based compensation to revenue
000.50.552.81
Graham number
8.127.356.264.643.81
ROIC
-0.46-0.41-0.44-0.56-0.97
Return on tangible assets
-0.41-0.61-0.49-0.62-0.82
Graham Net
2.350.970.850.870.25
Working capital
61.63M26M28.27M35.66M60.51M
Tangible asset value
65.02M32.99M32.61M40.03M19.76M
Net current asset value
61.57M24.3M26.81M34.43M15.7M
Invested capital
02.151.330.042.2
Average receivables
000243.5K2.45M
Average payables
1.07M766.5K596.5K676K1.49M
Average inventory
000-243.5K267.5K
Days sales outstanding
00019.68314.57
Days payables outstanding
1.68K554.67653.44255.25772.65
Days of inventory on hand
000-245.18320.47
Receivables turnover
00018.551.16
Payables turnover
0.220.660.561.430.47
Inventory turnover
000-1.491.14
ROE
-0.43-1.38-1.19-0.69-3.39
Capex per share
-0.03-0.06-0.03-0.01-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0000.060.04
Net income per share
-0.14-0.14-0.24-0.54-0.53
Operating cash flow per share
-0.12-0.11-0.1-0.32-0.32
Free cash flow per share
-0.13-0.11-0.1-0.32-0.32
Cash per share
0.861.391.21.841.5
Book value per share
1.011.511.210.920.43
Tangible book value per share
1.011.511.210.920.43
Share holders equity per share
1.011.511.210.920.43
Interest debt per share
0.040.020.030.920.99
Market cap
109.22M279.65M264.94M178.44M339M
Enterprise value
76.48M221.15M211.18M137.95M314.96M
P/E ratio
-4.83-11.48-6.03-1.8-3.44
Price to sales ratio
1.61K7.56K1.46K61.17170.52
POCF ratio
-22.05-60.93-56.74-12.05-23.01
PFCF ratio
-21.76-60.78-56.04-11.99-22.66
P/B Ratio
2.734.314.784.2217.15
PTB ratio
2.734.314.784.2217.15
EV to sales
1.12K5.98K1.16K47.29158.43
Enterprise value over EBITDA
-12.89-34.24-19.45-5.77-15.45
EV to operating cash flow
-15.44-48.18-45.23-9.31-21.38
EV to free cash flow
-15.23-48.07-44.67-9.27-21.06
Earnings yield
-0.05-0.02-0.04-0.14-0.07
Free cash flow yield
-0.05-0.02-0.02-0.08-0.04
Debt to equity
0.040.020.021.042.2
Debt to assets
0.030.020.020.450.53
Net debt to EBITDA
5.529.064.951.691.18
Current ratio
11.3123.879.918.064.55
Interest coverage
10914.18014.43-8.94
Income quality
0.840.70.420.60.6
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
46.9116.7332.626.8715.25
Research and developement to revenue
44.5674.0331.462.232.68
Intangibles to total assets
00000
Capex to operating cash flow
0.0100.0100.02
Capex to revenue
-0.97-0.3-0.32-0.02-0.11
Capex to depreciation
-0.17-0.08-0.44-0.18-1.05
Stock based compensation to revenue
17.2229.578.483.311.04
Graham number
1.82.192.553.352.26
ROIC
-0.14-0.1-0.21-0.27-0.32
Return on tangible assets
-0.13-0.09-0.18-0.26-0.3
Graham Net
0.751.311.060.710.25
Working capital
35.66M60.45M51.05M80.35M60.51M
Tangible asset value
40.03M64.85M55.4M42.3M19.76M
Net current asset value
34.43M59.3M49.98M36.88M15.7M
Invested capital
0.040.020.021.042.2
Average receivables
453K271.5K114.5K2.12M4.24M
Average payables
322K541K1.32M1.99M2.19M
Average inventory
-243.5K-243.5K0139.5K650.5K
Days sales outstanding
644.56136.2285.55125.64199.92
Days payables outstanding
735.97761.031.36K1.19K582.81
Days of inventory on hand
-706.9400173.17241.73
Receivables turnover
0.140.661.050.720.45
Payables turnover
0.120.120.070.080.15
Inventory turnover
-0.13000.520.37
ROE
-0.14-0.09-0.2-0.59-1.25
Capex per share
00000

VRCA Frequently Asked Questions

What is Verrica Pharmaceuticals Inc. stock symbol ?

Verrica Pharmaceuticals Inc. is a US stock , located in West chester of Pa and trading under the symbol VRCA

Is Verrica Pharmaceuticals Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $10. The lowest prediction is $10 and the highest is $10

What is VRCA stock prediction ?

What is Verrica Pharmaceuticals Inc. stock quote today ?

Verrica Pharmaceuticals Inc. stock price is $5.91 today.

Is Verrica Pharmaceuticals Inc. stock public?

Yes, Verrica Pharmaceuticals Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap